Palo Santo Fund
VC Fund
Palo Santo Fund is a VC fund focused on Biotechnology and Health Care. The future of mental wellness is being built today. Through its diversified investment fund, Palo Santo is positioned to increase the supply of clinically effective, affordable, and accessible mental health and addiction treatment solutions needed in today’s world.Supported by a rapidly growing body of evidence and strong FDA support,psychedelic-assisted treatments represent a paradigm shift in mental health care. Yet the emerging ecosystem of business opportunities is highly fragmented and, with a lack of institutional capital available, Palo Santo is targeting high growth opportunities within biotech & drug development, health care services, and digital health solutions led by passionate, experienced, and ethical management teams. These businesses are positioned to have a profound impact on treating conditions such as depression, PTSD, anxiety, OCD, drug and alcohol dependence, chronic pain, Alzheimer’s, and a range of inflammatory-related illnesses.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $35M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Palo Santo Fund invests in
Stages Palo Santo Fund invests in
Countries Palo Santo Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 8 (44%)
- Health Care 7 (39%)
- Medical 6 (33%)
- Mental Health 2 (11%)
- Pharmaceutical 2 (11%)
Stage
- Series A 6 (33%)
- Seed 5 (28%)
- Series B 3 (17%)
- Convertible Note 1 (6%)
- Venture - Series Unknown 1 (6%)
Country
- United States 9 (50%)
- United Kingdom 4 (22%)
- Canada 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Goldberg
Co-Founder
|
Co-Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $11M / Series B / Apr 06, 2026 | |
Reunion Neuroscience
|
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M / Series A / Sep 16, 2025 | |
Syndeio Biosciences
|
Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M / Venture - Series Unknown / May 27, 2025 | |
Xylo Bio
|
Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $8M / Seed / Jun 02, 2024 | |
Journey Clinical
|
Journey Clinical is a platform that provides services to member psychotherapy practices that are independently owned and operated, and in no way owns, directs, or controls the mental healthcare clinicians providing care. | $8.5M / Series A / Jan 24, 2023 | |
Gilgamesh Pharmaceuticals
|
Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $39M / Series B / Dec 15, 2022 | |
Sensorium Therapeutics
|
Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines. Founded in 2021, the company is based in Boston, Massachusetts. | $30M / Series A / Oct 04, 2022 | |
Kanna Health
|
Kanna Health is a preclinical stage company that is developing novel therapeutics based on kanna, also known as Sceletium tortuosum. Kanna is a medicinal succulent that has been used for centuries by the San hunter-gatherers of South Africa. | $3.8M / Convertible Note / May 15, 2022 | |
Fluence
|
Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge ofthe mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend. | $1.4M / Seed / Feb 15, 2022 | |
|
Fluence
|
Fluence offers continuing education and certificate programs in psychedelic integration and psychedelic-assisted therapy. Our programs are designed for licensed professionals and advanced graduate students who have an opportunity to work with patient populations. Although none of our courses have specific prerequisites, a basic working knowledge ofthe mental health field and practice of psychotherapy is helpful. Our programs are interactive; we engage in discussion, demonstration, self-reflection exercises, and role plays. Some of our classes and programs are reserved for licensed clinicians, but many are open to anyone who wishes to attend. | $1.6M / Seed / Nov 04, 2021 | |
| See all 18 investments → | |||
Co-Investors
Neo Kuma Ventures
6 deals together
Empath Ventures
4 deals together
Gaingels
4 deals together
Heron Rock Fund
4 deals together
JLS Fund
4 deals together
PsyMed Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Palo Santo Fund invest in?
Palo Santo Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Palo Santo Fund?
Public channels for Palo Santo Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Palo Santo Fund?
The team at Palo Santo Fund includes Daniel Goldberg (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
